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Foreword
This monograph is a publication of original research focused on biopharmaceutical sector Knowledge
Management (KM) methodologies and capabilities. The authors, through their research, have developed
models, tools and processes which can assist the sector gain greater clarity of the value and merits that KM
can offer to organisations.
Kane’s research was driven by a determination to close the gap from KM theory to practice.
Her research addresses a void of research in, and understanding of, the concept of KM in the biopharma
sector, and proposes a foundational Pharma KM Blueprint (Kane 2018). The Pharma KM Blueprint illustrates
holistic integration of core KM principles, models and tools to deliver real benefits to the patients and the
business.
The Pharma KM Blueprint is comprised of several elements, including:
•

Recognising Knowledge as an Asset - Identifies the need to value and maintain knowledge assets in
the same way as physical assets within an organisation

•

The Pharmaceutical Product Knowledge Lifecycle Model (PPKL) - Addresses the challenge of
enabling knowledge flow in order to increase visibility, access to and use of the product and process
knowledge assets across the product lifecycle

•

The House of Knowledge Excellence (HoKE) Framework – Demonstrates a framework developed
to implement a systematic KM programme linked to strategic objectives of an organisation,
incorporating KM practices, pillars, and enablers to support the effective management and flow of
knowledge assets.

•

A Knowledge Management Effectiveness Evaluation (KMEE) - A practical KM diagnostic tool
that may be used to identify and evaluate areas of opportunity and to track progress on closing
knowledge gaps.

This research has already spawned additional research on the KM topic, including research by co-author
Lipa further exploring the PPKL topic of tacit knowledge in technology transfer. Lipa’s research is on-going,
but an early output is a confirmation that knowledge transfer as part of technology transfer is often not
effective. Lipa goes on to propose a framework for enhancing knowledge transfer known as the Knowledge
Transfer Enhancement (KTE) Framework. Research is continuing on this topic and will be the subject of future
publications.
It is hoped that these research outputs and corresponding dialogue within the biopharma industry will lead
to meaningful improvements for the industry and for the patients who depend on it.

A Monograph from TU Dublin Academic Press 2020
© Paige Kane and Martin Lipa

3

Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry

Acknowledgements
The authors would like to thank our PhD supervisors, Professor Anne Greene and Dr Nuala Calnan for their
guidance and support through many years of researching Knowledge Management in the Biopharmaceutical
Sector.
In addition, the authors would like to acknowledge the TU Dublin Pharmaceutical Regulatory Science Team
(PRST) for their willingness to ideate on our topic of KM and its relation to QRM and patient outcomes.
The authors are indebted to the monograph editorial team of Professor Anne Greene, Dr Nuala Calnan, and
Dr Anne Murphy for their assistance in transforming PhD thesis outputs into a consumable biopharmaceutical
sector monograph.
Paige Kane, PhD and Martin Lipa, MS

4

A Monograph from TU Dublin Academic Press 2020
© Paige Kane and Martin Lipa

Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry

Author and Editor Profiles
Paige Kane • PhD, CPIP
Paige Kane PhD, CPIP, is a Director in the Merck Manufacturing Division, and a member of
the MMD Knowledge Management (KM) Center of Excellence. She is an industry leader
with over 30 years’ experience, including with six pharmaceutical companies and the
US Government, spending the past 13 years designing and leading KM programmes and
approaches for the Pharmaceutical Industry. Prior to her work in KM, Kane led multiple
Quality Systems Groups focusing on Automation Compliance Strategies, Change Control,
Document Management, Computer/Equipment Validation and Data Integrity for new
biotechnology facility start-ups and operations in the US and Ireland. She has experience
working across the pharmaceutical product lifecycle in GLP, GCP (Clinical trial oversight and
supplies) and GMP in Human and Animal Health.
Kane has led several industry Strategic Teams including ISPE CoPs, and currently leads the
ISPE KM Good Practice Guide authoring team. Kane has participated in authoring several
industry guidance documents and contributed to many conference sessions and industry
papers. She is a co-editor of, and multi-chapter contributor to, ‘A Lifecycle Approach to
Knowledge Excellence in the Biopharmaceutical Industry’ (2018).

Martin Lipa • Executive Director at MSD
Martin (Marty) Lipa is an Executive Director at MSD where he leads the Knowledge
Management Center of Excellence for Merck Manufacturing. In his current role Marty
is responsible for a holistic KM Strategy addressing standardised KM approaches as well
as enabling elements of people, process and technology. Marty has over 12 years of
KM experience, and related experience as a Certified Lean Six-Sigma Black Belt and in
transformational change management and IT. Prior to working in his KM role, Marty had
experience in various engineering roles, Technical Operations, shop-floor automation,
new GxP facility start-up and Information Technology at sites in the US, U.K., Ireland and
Singapore. Marty is an active member of the KM community as a regularly invited speaker
on KM. He has published several industry- specific works, including as contributing editor to
‘A Lifecycle Approach to Knowledge Excellence in the Biopharmaceutical Industry’ (2018),
as well as papers in various journals.
Marty is currently pursuing his PhD at the Technological University Dublin with a focus
on Knowledge Management as an enabler of product and process understanding, with a
specific focus on Technology Transfer.

A Monograph from TU Dublin Academic Press 2020
© Paige Kane and Martin Lipa

5

Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry

Prof. Anne Greene • Head, Pharmaceutical Regulatory Science Team (PRST),
Technological University Dublin
Anne Greene leads the Pharmaceutical Regulatory Science Team (PRST) in TU Dublin,
where she is also a senior lecturer and director of several MSc. and BSc. Pharmaceutical
Programmes, including the TU Dublin MSc in Pharmaceutical Validation Technology. She
has supervised several students to PhD awards in areas of Quality Risk Management,
Knowledge Management, Operational Excellence and PAT.
Prior to embarking on an academic career, Anne worked at a senior level for several years in
the pharmaceutical sector in Validation and Technical Management roles. She has a PhD in
Synthetic Organic Chemistry from University College Dublin, and is currently a member of
committee of the Irish Chapter of PDA. Anne is also on the Board of Directors of Regulatory
Science Ireland (RSI) and is chair of the Corporate Development Committee.

Dr Nuala Calnan
Dr Nuala Calnan is a twenty-five year veteran of the pharmaceutical industry. Her work
as a consultant, academic, author and commentator is directed toward the delivery of
patient-focused excellence and has included research for FDA (USA), HPRA (Ireland) and
other regulatory agencies on patient safety and product quality in the manufacture and
distribution of drugs.
Her current areas of consultancy and research include quality risk management, data
integrity, knowledge excellence, metrics design, cost of quality and building patient-focused
quality cultures. Nuala co-leads the ISPE Quality Culture Team and is a founding member of
the ISPE/ PQLI Task Team on Knowledge Management.

Dr Anne Murphy
Dr Anne Murphy is an Emeritus Research Fellow in TU Dublin. She has had a long career
in education as a teacher, academic development practitioner, research supervisor and
project manager, specialising in recent years in recognition of prior learning, work-based
learning, qualifications frameworks development and TVET systems in the EU and in Serbia,
Turkey, Macedonia, Kosovo, Afghanistan, Uzbekistan, Kazakhstan, Russia and Malaysia.
She founded the first TU Dublin (formerly Dublin Institute of Technology DIT) open access,
online journal in 2003, was instrumental in developing the concept of the TU Dublin
Academic Press and was a long-term reviewer for Emerald Publishing. She is currently a
CORU public interest panel member for regulation of qualifications in the health and social
care professions in Ireland.

6

A Monograph from TU Dublin Academic Press 2020
© Paige Kane and Martin Lipa

Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry

Contents
CHAPTER ONE
Monograph Background and Context .......................................................................... 8
CHAPTER TWO
Managing Knowledge as an Asset ............................................................................. 12
2.1
2.2
2.3
2.4

Valuing Knowledge as an Asset......................................................................................12
Critical Knowledge........................................................................................................16
Stemming the Loss of Critical Knowledge.........................................................................18
Conclusion....................................................................................................................19

CHAPTER THREE
Pharmaceutical Product Knowledge Lifecycle (PPKL) Model ............................................20
3.1
3.2
3.3
3.4
3.4.1
3.4.2
		
3.5

Product Knowledge – the Regulatory Landscape............................................................. 20
The ICH Q10 Product Lifecycle...................................................................................... 22
Connecting Product and Process Knowledge................................................................... 23
Reimagining the ICH Q10 Product Lifecycle Model.......................................................... 24
Reimagining the ICH Q10 Product lifecycle Model - Technology Transfer.......................... 25
Reimagining the ICH Q10 Product lifecycle Model Technical Product Support and Continual Improvement.................................................... 29
The Pharmaceutical Product Knowledge Lifecycle (PPKL) Conclusions.................................31

CHAPTER FOUR
The House of Knowledge Excellence (HOKE) ................................................................32
CHAPTER FIVE
Knowledge Management Effectiveness Evaluation (KMEE) ...............................................34
5.1
5.2
5.3
5.4
5.4.1
5.4.2
5.5

Evaluating Knowledge Management Maturity, Knowledge Flow, and Improvement............ 34
APQC’s Knowledge Management Capability Assessment Tool™ (KM-CAT™).................... 36
Need for a supplemental tool for localized functional KM Assessments............................. 39
Development of the Knowledge Management Effectiveness Evaluation (KMEE) Tool:........... 40
Scoring Methodology................................................................................................... 45
KMEE Reporting and KM Plan – A Roadmap to KM Capability Improvement.................... 47
Conclusion................................................................................................................... 47

CHAPTER SIX
Evolving Research: Presentation of a Framework to Enhance Knowledge Transfer.................48
CHAPTER SEVEN
References...............................................................................................................50

A Monograph from TU Dublin Academic Press 2020
© Paige Kane and Martin Lipa

7

Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry

1.

Chapter One
Monograph Background and Context

In 2005 The International Conference on Harmonisastion (CH) published a concept paper for ICH Q10
Pharmaceutical Quality System (International Conference on Harmonisation, 2005a) , where the topic of
knowledge management (KM) made a formal entrance to the global regulatory landscape for the first time,
and was identified as one of the two enablers underpinning an effective Pharmaceutical Quality System (PQS),
along with quality risk management (QRM), as shown in the ICH Q10 diagram (Figure 1.1).

Figure 1.1 — ICH Q10 PQS Diagram inclusive of a product lifecycle (updated to enhance
graphic quality)- (International Conference on Harmonisation, 2008)

Even though KM only found its way formally into the biopharmaceutical sector regulatory guidance in 2005,
in fact KM concepts had been widely discussed in many other sectors for a quarter of a century or more. Its
appearance in an official regulatory guidance document placed additional emphasis on the topic within the
sector, as noted by one EU regulator: “If something isn’t specifically required by some type of regulatory
guidance (financial, safety, good manufacturing practice, etc.), even if it’s good for business, it is often difficult
to drive adoption”. (O’Donnell, K., personal communication, June 3, 2018).
In 2015, the 10 year anniversary of ICH Q10, a two-day Knowledge Management international conference
KM Dublin 2015 (“Knowledge Management From Discovery to Patient: Enabling Knowlege Flow, Delivering
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Safe & Effective Products,” 2015), jointly organised by the Irish Regulatory Agency (HPRA), Regulatory Science
Ireland (RSI) and the Pharmaceutical Regulatory Science Team (PRST), was held in Dublin Castle, Ireland.
KM Dublin 2015 aimed to drive the knowledge management discussion forward for the biopharmaceutical
sector. and was themed Enabling Knowledge Flow, Delivering Safe & Effective Products. This symposium
attracted over one-hundred and forty attendees. It was the first of its kind to bring together international
regulators, life science industry practitioners, academics and KM thought leaders to discuss and explore the
integration of knowledge management and risk management in the development, manufacture, surveillance
and regulation of biopharmaceutical and medical device-related health products.
While it has been over a decade since KM emerged as a Pharmaceutical Quality System (PQS) enabler in
ICH Q10, there is evidence that knowledge management is not well understood as a management practice
because of the considerable focus placed on the science, technology and regulation necessary to deliver the
sector’s complex array of biopharmaceutical products (Lipa, Kane, & Greene, 2019). In 2014, the authors of
this monograph embarked on this research study into the topic of KM, and as the study progressed, so too did
the level of industry interest in, and discussion on, the topic of knowledge management.
The research examined industry KM methodologies and capabilities in order to gain insights into the level
of maturity and understanding of KM within the biopharmaceutical sector. In addition, models, tools and
processes were developed to assist the sector gain greater clarity of the value and merits of KM and offer
ways to “unlock” the knowledge necessary to deliver the next generation of therapeutics.
While a thorough literature review found no shortage of academic references related to the broad field
of knowledge management, a clear gap emerged between academic exploration and practical utilisation
specifically in the Biopharmaceutical Sector. The research focused on addressing this gap by examining the
then current KM methodologies and capabilities in order to gain insights into how to best utilise existing,
new, and emerging biopharmaceutical knowledges to realise the ambitions of ICH Q10, stated as, ‘enhance
the quality and availability of medicines around the world in the interest of public health’, (International
Conference on Harmonisation, 2008). In addition, the research endeavored to close the gap between KM
theory and practice and provide KM practitioners with fit-for-purpose models in the biopharmaceutical
environment.
The main output from this research study is a new framework entitled The Pharma KM Blueprint which is
presented in Figure 1.2 below, and discussed in this monograph.
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Figure 1.2 — The Pharma KM Blueprint- (Kane, 2018a)

The model is built on the Principle of the need to Manage Knowledge as an asset. It comprises of two
Frameworks that provide methods of how to Manage Knowledge as an asset, and a KM Diagnostic Tool,
which can be used to evaluate the Effectiveness of an organisation’s KM approach.
Subsequent chapters of this monograph discuss the elements of the Pharma KM Blueprint as follows:

10

•

Chapter 2 - Managing Knowledge as an Asset – addresses the need to value and maintain
knowledge assets in the same way as physical assets within an organisation

•

Chapter 3 – The Pharmaceutical Product Knowledge Lifecycle Model - addresses the challenge of
enabling knowledge flow in order to increase visibility, to access and use the product and process
knowledge assets across the product lifecycle

•

Chapter 4 - The House of Knowledge Excellence Framework – demonstrates a framework
developed to implement a systematic KM programme linked to strategic objectives of an
organisation, incorporating KM practices, pillars (people, process, technology, governance), and
enablers to support the effective management and flow of knowledge assets.

•

Chapter 5 – A Knowledge Management Effectiveness Evaluation - provides a practical KM
diagnostic tool that may be used to identify and evaluate areas of opportunity and to track progress
on closing knowledge gaps.

A Monograph from TU Dublin Academic Press 2020
© Paige Kane and Martin Lipa

Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry
In addition, the monograph concludes with a final chapter (Chapter 6) in which a high-level overview of
subsequent research by Lipa is given, building on the research of Kane, into Knowledge Management during
Technology Transfer. In that chapter, a framework to improve KM effectiveness at Technology Transfer is
presented.
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2.

Chapter Two
Managing Knowledge as an Asset

This Chapter presents the first element of the Pharma KM Blueprint, namely, managing knowledge as an
asset. In a seminal publication from 2014 Lipa et al. described the paradox of how the ability to transfer
and apply knowledge is acknowledged as a competitive advantage, but that however, “knowledge is seldom
treated like a crucial asset” (Lipa, Bruno, Thien, & Guenard, 2014). This topic was further explored at a
breakout group led by the authors in the KM Dublin 2015 conference, resulting in a deeper exploration of
the knowledge asset concept and greater understanding of what constitutes crucial or critical knowledge
(Kane, 2018b) Participating in this breakout group were key biopharmaceutical industry experts, together
with thought leaders from the American Productivity and Quality Center (APQC).

2.1

Valuing Knowledge as an Asset

Linking quality and knowledge management has been, and remains, a foundational component of the mission
of APQC. APQC’s founder Jack Greyson was one of the creators of the Malcolm Baldridge National Quality
Award (MBNQA). The MBNQA recognises US organisations for performance excellence. Not surprisingly then,
knowledge management is a core capability included in the evaluation process for the MBNQA award, and
it is in supporting materials for applying for this award that a definition for “knowledge assets” appears. This
definition of a knowledge asset provides, in the opinion of the authors, the most comprehensive definition of
knowledge assets in the literature review undertaken for this body of research. This definition and description
are given below:
‘The term “knowledge assets” refers to the accumulated intellectual resources of your
organisation. It is the knowledge possessed by your organisation and its workforce in
the form of information, ideas, learning, understanding, memory, insights, cognitive and
technical skills, and capabilities. Your workforce, databases, documents, guides, policies and
procedures, software, and patents are repositories of your organisation’s knowledge assets.
Knowledge assets are held not only by an organisation, but reside within its customers,
suppliers, and partners as well. Knowledge assets are the “know how” that your organisation
has available to use, to invest, and to grow. Building and managing its knowledge assets are
key components for your organisation to create value for your stakeholders and to help sustain
overall organisational performance success.’ (Steel, n.d.)

Building on this concept of knowledge assets, Lim et al. noted, that for organisations to succeed, they ‘have
to view knowledge as an asset and manage it effectively’ (Lim, Ahmed, & Zairi, 1999, p. S616).
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Based on 25 years of the personal experience of the authors, validated by the themes elicited from the
industry consultations and discussions at KM Dublin 2015 conference, a key observation was that:

The biopharmaceutical sector had not yet come to the realisation that knowledge is an
asset, as demonstrated by the lack of formal processes and/or resources to manage its
knowledge as an asset. Knowledge assets are not treated as equivalent to physical assets,
such as plant, equipment or lab bench technologies.

In valuing knowledge assets, the authors considered that, in fact, physical assets and knowledge assets have
several characteristics in common as follows:
•

Both classes of assets can appreciate or depreciate: Not all knowledge has the same value over
time.

•

The more the asset is used, the more value it creates: When a bioreactor is run at high capacity, it
brings more value to the business than when sitting idle. Similarly, if a knowledge asset is not used,
it provides little value to the person who captured and stored it, or to the business.

•

Both physical and knowledge assets can be traded: For example, in the form of sharing explicit
knowledge (a report or training programme) or sharing an expert who has deep tacit knowledge
about a topic within your network.

•

There is a market value for a knowledge asset: In the case of tacit knowledge, when tacit
knowledge is needed, and it isn’t available, it is possible (in some cases) to purchase that
knowledge, such as by hiring experts to troubleshoot a critical utility system, engaging consultants,
or the addition of knowledgeable/experienced new full-time staff. Conversely, organisations that
build up a deep internal knowledge often sell their services to others e.g. in 1991 NNE (Novo Nordisk
Engineering) began selling their pharmaceutical engineering services to others outside of their own
company. In the instance of explicit knowledge, it is possible to purchase standards, reports or other
forms of codified knowledge to enhance the body of knowledge within an organisation.

Dr Nick Milton of Knoco has written on the theme of knowledge assets and describes the traditional field of
physical asset management as ‘well studied’. He suggests learning opportunities in linking the methodologies
of physical asset management to knowledge asset management (Milton, 2014). Milton outlines the four
stages of an asset lifecycle, citing the Asset Management Accountability Framework developed by the State
of Victoria (AUS), as a starting point to consider when managing knowledge assets, as in Figure 2.1 below.
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Figure 2.1 — Four stages of the asset lifecycle (State of Victoria Department of Treasury and
Finance, 2016, p. 11)

The four stages outlined in the framework include: Planning, Acquisition, Operations and Disposal. Reflecting
on these stages, the authors suggest in Table 2.1 what this might mean in terms of KM for a biopharmaceutical
organisation, and posed key questions to address in the four stages for knowledge assets.
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Table 2.1 — Key questions to address in the four stages for knowledge assets

Planning (including strategy and risk assessment)
•

What knowledge is critical?

•

Where does it fall within the regulatory framework (GLP, GCP, GMP)?

•

Is it tacit or explicit?

•

What is the risk of losing this knowledge?

•

Do we have the systems we need to ensure this knowledge can flow to those who need it, when they need it?

Acquisition: process of procurement
•

How will this knowledge be generated?

•

Will this knowledge creation occur via a business process (e.g. change management, deviation management,
technology transfer, business development activities)?

•

Will this knowledge creation occur via a technical process (e.g. experiments, technical scale up, lab-testing,
manufacturing, data analytics/ SPC review etc.)?

•

What mechanisms are available to capture and store this knowledge once created?

Operation
•

Applying the KM lens to this stage requires a focus on capturing knowledge in the flow of work during
operations.

•

KM approaches such as Communities of Practice (CoPs) and lessons learned activities, greatly enhance the
ability to capture and share knowledge assets in the flow of work.

•

For physical assets it is the norm to have dedicated roles for personnel to maintain these assets on a regular
basis. This maintenance role, or knowledge curation role, is not yet commonplace in regard to knowledge
assets.

•

While there may be an information technology person responsible for a system that contains explicit
knowledge, but who maintains the knowledge assets to ensure they are timely, relevant, and accessible?

Disposal

1

•

Like physical assets, knowledge assets too have an end of life.

•

Processes should exist to identify and remove knowledge assets that are no longer relevant1: not only is it
costly to manage old assets, it also could make it more difficult to find relevant / current assets in a timely
manner.

•

As with maintenance, a role should exist to manage the whole lifecycle of the knowledge asset, and that
includes a systematic process for disposal.

Removal of knowledge assets may be subject to records retention policies.
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Having presented the rationale that knowledge is an important asset and should be considered on par with
a physical asset, the next important step forward in knowledge as an asset component of the Pharma KM
Blueprint explores the concept of critical knowledge.

2.2

Critical Knowledge

ICH Q10 Pharmaceutical Quality System (PQS) defines the product life cycle stages of a pharmaceutical product
as: Product Development, Technology Transfer, Manufacturing, and Product Discontinuation. Throughout
these individual product lifecycle stages a variety of data, information, and knowledge are created and used.
A plethora of pharmaceutical GxP regulations 2 outline minimum expectations regarding the management
of the variety of data and information related to product safety and efficacy, as well as manufacturing and
testing operations.
As the industry and technology have matured, companies have increased their organisational capabilities
for capturing and processing their day-to-day data and information. Advances in terms of Continued Process
Verification (CPV), Statistical Process Control (SPC), smart manufacturing, data analytics, and now even
artificial intelligence (AI) capability, have all contributed to the growing “data lakes” across the sector. Indeed,
Oliver notes that pharma data are doubling every five months and that:

In recent years, the pharma industry has invested heavily in “data lake” style technologies.
Essentially, capture the data first and hope to find a use for it later. While the amount of data
captured has increased, we’re still waiting for the outcomes. (Oliver, 2018)

A key question for the authors is what, if any, of this data might be considered critical?
Furthermore, the authors pondered that if technology is not delivering the desired outcomes, what about
the people? Are they delivering desired outcomes? While the 1990’s brought an early focus on the role of
people in the knowledge creation process (Nonaka & Takeuchi, 1995), more than 30 years later, despite an
increasing regulatory attention on the need for effective risk-based decision- making, the biopharmaceutical
sector is still lagging in terms of unlocking and connecting tacit knowledge across their organisations. One
wonders how well the sector actually performs in regard to leveraging its knowledge: in short, how well is the
sector using what it already knows?
Reflecting on how well the sector is doing in identifying its critical knowledge, one does not need to look
further than the ISPE Drug Shortages Survey Report (ISPE, 2013, p. 6), where a significant number of
respondents noted that ‘production system issues leading to drug shortages or near misses were present
2
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(i.e. Good Manufacturing Practices (GMPs), Good Clinical Practices (GCP) and Good Laboratory Practice (GLP) – collectively referred
to henceforth as “GxP”)
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during technology transfers or product development’. Indeed, Professor Jose C. Menezes, an expert in Quality
Risk Management from the Technical University of Lisbon, also highlights the lack of “using what we know”
as a case of institutional amnesia and evidence of why we continue to see repeated FDA 483’s and Warning
letters3 within organisations:

“The [biopharmaceutical] industry has no memory. We keep repeating the same mistakes
again and again.” Prof. Jose C. Menezes. September 16, 2016 ISPE Annual Meeting, Atlanta
GA USA

An APQC benchmarking report published in 2018 also confirms that the biopharmaceutical sector has been
slow to adopt KM approaches. It reports that only 4% of biopharmaceutical KM programmes have reached a
standardised maturity level of “3” or better, in comparison to 18% across all other sectors. (Trees & Hubert,
2018, p. 50). In contrast, an earlier, non-pharma specific survey, this time conducted by KPMG, reported that
79% of respondents believed that KM can play an “extremely significant” or a “significant” role in improving
competitive advantage (KPMG, 2000, p. 15). For other sectors KM approaches embedded into the flow
of work have been credited with employee engagement as well as considerable sources of cost savings.
A specific example comes from El Paso, an oil and gas company, where KM efforts were focused to foster
expertise within the firm and share technical knowledge across the organisation. El Paso targeted first-year
savings of $500,000, but in fact delivered over $1.2 million in savings in the first year (APQC, 2012b).
Slow KM adoption also featured in the researchers 2017 ISPE Pharmaceutical KM Survey4, where only 25%
of respondents indicated that KM was embedded in the way they work. Therefore, with KM adoption in the
biopharmaceutical sector clearly lagging behind other sectors, and the blight of an industry-wide case of
amnesia, one could question if product and process knowledge is delivering value to either our businesses,
or, more importantly, to our patients.
Arguably, a key challenge inherent in those data and information capture is the conversion of those data and
information into knowledge, and the identification, retention and perhaps most importantly of all – the use
of the critical knowledge (that may be explicit or tacit) in order to speed decision-making, enable greater
insights to support risk management and drive operational excellence through continuous improvement.
Returning to the development phase of the biopharmaceutical lifecycle, ICH Q8 - Pharmaceutical Development
(International Conference on Harmonisation, 2009), placed an emphasis on product and process understanding.
However, it is clear from this research that there are many more sources of organisationally critical knowledge

3

FDA 483’s and Warning letters are written notices of non-compliance with federal regulations. A Warning letter may be issued for a
significant infraction and could result in the loss of licensure and other penalties.

4

Although not statically relevant, low participation in the survey may also point towards a general lack of maturity and awareness of
KM within the sector
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beyond that knowledge which is directly related to the development, or even manufacture, of a given product
and process, such as patient usage, post-market surveillance, knowledge of business processes, etc. This is
further discussed in the next section.

2.3

Stemming the Loss of Critical Knowledge

In the opinion of the authors, in addition to product and process knowledge highlighted in the ICH Guidance
documents and GxP regulations, critical knowledge may also come from sources beyond the traditional “GxP”
lens. This includes capturing lessons learned, expertise or ‘know-how’ of how things work, whether it be
sourced as a technical element or an input or output from a complex business process, and even knowledge
gained from continual improvement programmes and projects.
The knowledge of how things work and how things get done is also critical to an efficient and effective
workflow, and often has a direct impact on the ability of the organisation to consistently deliver high quality
medicines to the patient. Often times this knowledge is not recognised or valued as ‘critical’ until someone
leaves their role, or even more challenging, exits the company. By which point it is difficult or impossible to
recover or reconfigure the original knowledge asset(s). The challenge of knowledge loss is not specific to the
biopharmaceutical sector. However, there may be a false sense of security regarding the ability to recreate
such knowledge within the sector due to the traditional focus on retention of regulated data, records, and
information. However, “know-how” often provides the key necessary to unlock the critical knowledge from
within these retained records. Without the “know-how”, retained data and information may never progress
up the hierarchy to be converted into useful knowledge. Therefore, in the biopharmaceutical sector it is
important that knowledge retention strategies should never be mistaken for record retention policies and
procedures. Knowledge retention is a much broader organisational capability, never more so than when the
outsourced supply chain is also considered. Davenport et al. remind us that if you are ‘renting knowledge,
make sure you take steps to retain it’ (Davenport & Prusak, 1998, p57.). Supplier Technical Agreements (TAs)
should, but often don’t, incorporate clauses related to the knowledge that emerges over the course of the
contractual arrangement with a supplier.
Knowledge mapping is one valuable KM practice that may be utilised to help identify knowledge and its
relative importance to the organisation. A proven knowledge mapping tool, specifically designed for use
within the biopharmaceutical sector, has been developed and used successfully by one of the authors of
this monograph (Kane, 2018b). Finally, knowledge mapping is one of the core KM practices identified in the
overall House of Knowledge Excellence Model (Kane & Lipa, 2018), which is described in detail in Chapter 4,
and which is the third element of the Pharma KM Blueprint.
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2.4

Conclusion

In conclusion, the authors acknowledge the complications which arise in the biopharmaceutical landscape
specifically in respect to the regulatory expectations to capture, store, and validate a range of explicit
knowledge. As discussed, not all knowledge or content are of equal value or regulatory importance. This
concept is aligned with the recommendation in the ISPE GAMP© Electronic Records & Signature guidance
(ISPE Guide, 2005) noting the need for ‘application of appropriate controls commensurate with the impact of
records and the risks to those records.’ Pragmatic KM guidance in this field also advocates that the manner
in which explicit knowledge and content is stored and curated5 should be commensurate with the relative
importance/criticality of that knowledge.
This chapter has presented the need to manage knowledge as an asset and shown how physical assets and
knowledge assets have several characteristics in common, including the necessity to have dedicated roles
for personnel to maintain these knowledge assets on a regular basis. This maintenance role, or “knowledge
curation” role, is not yet commonplace in this sector. Chapter 3 will outline the next key element blueprint,
the Pharmaceutical Product Knowledge Lifecycle (PPKL) Model, which discusses the importance of enabling
knowledge assets to flow across the product lifecycle.

5

curate something (especially on the Internet) to collect, select and present information or items such as pictures, video, music, etc.
for people to use or enjoy, using your professional or expert knowledge. Oxford Learners Dictionary online.
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3.

Chapter Three
Pharmaceutical Product Knowledge
Lifecycle (PPKL) Model

This chapter presents the second element of the Pharma KM Blueprint, namely a Pharmaceutical Product
Knowledge Lifecycle (PPKL) model, adapted from the product lifecycle presented in ICH Q10. The motivations
to develop this knowledge lifecycle are twofold. Firstly, the terms, knowledge and knowledge management
(KM) are referenced across ICH guidance documents Q8 -Q11 (International Conference on Harmonisation,
2012) and in the ICH Q12 (International Conference on Harmonisation, 2019) in over 200 instances. Yet more
specific regulatory guidance setting out the expectations for knowledge does not exist. Without a focused
discussion on the product lifecycle it is difficult to understand how such knowledge is created, connected
and utilised across the lifecycle. Industry consultation undertaken as part of our research identified a specific
request to better define the relationship between the product lifecycle and KM (Kane, Lipa, & Hubert, 2015).
Secondly, in the context of making product knowledge visible, enabling knowledge flow, and increasing
availability, the authors believe the lifecycle phases as depicted in ICH Q106 do not represent actual practice
in the context of knowledge management and knowledge flow. They therefore offer a re-imagined model to
emphasise the critical role that knowledge plays in the pharmaceutical product lifecycle. It is the opinion of
the authors that the very absence of knowledge from the product lifecycle model, depicting how the product
and process knowledge assets are created and transferred into other organisational knowledge outputs,
directly contributes to the ambiguity and compartmentalisation of lifecycle knowledge, and greatly inhibits
the intended benefits sought by the ICH suite of quality documents.

3.1

Product Knowledge – the Regulatory Landscape

ICH Quality guidance issued during the period of 2005-2012 created awareness of risk-based science
approaches to ensuring pharmaceutical product quality. The ICH Quality guidance documents share common
expectations of leveraging product and process knowledge as an enabler to effective risk-based science.
In addressing the need to process post-approval changes in a more predictable and efficient manner, the ICH
Q12 concept paper was issued in 2014 entitled, Technical and Regulatory Considerations for Pharmaceutical
Product Lifecycle Management (International Conference on Harmonisation, 2014). The ICH Q12 concept
paper identified gaps in realisation of intended benefits.

6
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The product lifecycle is depicted in ICH Q10 Annex 2 page 17 (International Conference on Harmonisation, 2008)
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“There is currently a lack of a harmonised approach on technical and regulatory considerations
for lifecycle management. While the concepts in ICH Q8, Q9, Q10 and Q11 provide opportunities
for a more science and risk-based approach for assessing changes across the lifecycle, several
gaps exist which limit full realisation of intended benefits.”

In November 2019 ICH Q12 was published (International Conference on Harmonisation, 2019) and it focuses
on established conditions and post-approval changes with modest additional KM guidance. Q12 highlights
the following:
a) A ‘PQS includes appropriate change management, enabled by knowledge management, and
management review’
b) ‘Provisions should be made for sharing knowledge (e.g. in quality agreements and/or contracts) that
relates to product and process robustness or otherwise informs changes between the MAH and
relevant manufacturing stakeholders’
c) In addition to the individual sources of information, there should be a holistic view of quality
performance for a product or product family.
Figure 3.1 depicts the diagram from the Q12 which places highlights Knowledge Management as a key
component of the Change Management process.

Figure 3.1 — ICH Q12 - Putting Knowledge Management as a key component of Change
Management (International Conference on Harmonisation, 2019, p. 19)
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The authors suggest that organisations could greatly benefit from further guidance to assist in forming a
holistic end-to-end (E2E)7 view of product knowledge assets, similar to the Q12 recommendation for a holistic
view for quality performance. One path towards further guidance could be achieved if regulatory guidance
for KM8 was approached in the same way as ICH Q9 was developed for QRM. However, while this route could
reduce the current levels of ambiguity, the authors conclude that expectations from a regulatory perspective
could in fact be over-burdensome, and therefore not welcomed by the sector as a whole.

3.2

The ICH Q10 Product Lifecycle

Returning to ICH Q10, the product lifecycle provides a foundation of shared understanding for the lifecycle
phases of a medicinal product as shown in Figure 3.2 below.

Figure 3.2 — ICH Q10 PQS Diagram inclusive of a product lifecycle (updated to enhance
graphic quality) (International Conference on Harmonisation, 2008, p. 21)

The authors suggest that, not only is KM an enabler of the PQS as depicted in the ICH Q10 model, but it is in
fact fundamental to how the sector creates value for patients and stakeholders since it enables end-to-end
visibility, flow and availability of what is known about the products.
Although the suite of ICH guidance highlights the importance of capturing and building on product and
process knowledge, recommendations on how this might be achieved are not included. Understanding the
flow between the product lifecycle phases, the range of supporting business processes and the needs of the
7

E2E refers to the product lifecycle from product development through product discontinuation

8

The authors are not specifically advocating for regulatory guidance for KM – as evidenced in the industry consultation events, any
guidance, either by industry or regulators would be beneficial
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myriad of groups involved in capturing knowledge assets can leave organisations in a quandary as to how
to enhance visibility and utilisation of the behemoth of product and process knowledge gathered over the
lifecycle. A lifecycle approach to KM provides a unique value proposition to help an organisation looks endto-end at the flow of its knowledge assets, transcending organisational structure, geographies and other
boundaries. In practice, enabling knowledge flow across the multiple phases of the product lifecycle can be
very difficult.

3.3

Connecting Product and Process Knowledge

Product and process knowledge is created constantly through a variety of business processes, dialogues and
other interactions between colleagues. This knowledge is stored across many different locations (i.e. formal
and informal repositories and other IT systems) as well as in the heads of subject matter experts. Returning
to a quote from O’Dell that “knowledge is sticky’, two challenges were identified by the authors in connecting
knowledge, the first of which is enhancing the visibility of lifecycle knowledge assets. and the second is
enhancing the flow of those knowledge assets. These were echoed in the BPOG KM Technical Roadmap
(BioPhroum Operations Group, 2017) where the team noted:
The biopharmaceutical community (the industry and its stakeholders) can advance IT tools
and systems by articulating what knowledge and knowledge flow is, defining organisational
knowledge flow challenges, developing best practices and biopharmaceutical use cases
… and creating real-time, networked knowledge management systems throughout the
biopharmaceutical industry.

The authors, reflecting on the insights gain from the industry consultations and direct experience, summarise
possible reasons for these challenges as follows:
•

Guidance is lacking on product lifecycle knowledge lifecycle and the knowledge generated within
the lifecycle phases and activities

•

The industry recognises there is a problem, but it is difficult to articulate

•

More effectively managing product and process knowledge is a broad issue, and with a clear benefit
to patients and to the business (reliable supply, access to medicines and lower costs with process
improvements)

In an attempt to address these challenges, the authors turned to ICH Q10 and suggested a modified version
of the lifecycle depiction, as discussed in the next section.
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3.4

Reimagining the ICH Q10 Product Lifecycle Model

Every day that the pharmaceutical product is manufactured, more knowledge is created and more is learned
about the process and the product. Taking into account the tremendous amount of knowledge that is
generated across the organisation (internal and potentially external to the Marketing Authorisation Holder)
across the lifecycle of a product, the authors asserts that:
•

If a primary goal of ICH Q10 is product realisation which requires that an organisation applies the
best of what it knows (its collective knowledge and experience) in its decision-making for that
product

And,
•

If every product interaction – whether formal or informal – is viewed as an opportunity to deepen
the knowledge of the product….

this requires a re-imagination of the ICH Q10 depiction of the product lifecycle. The authors believe a new
articulation of the lifecycle could be developed which would better align with the non-linear nature of product
development, manufacture and knowledge transfer throughout the life of the product.
The authors propose four areas of opportunity to enhance the ICH Q10 model.
1. Technology Transfer could be considered as a Technology and Knowledge transfer activity that
occurs several times during the lifecycle of a product. (Therefore, remove Technology Transfer as a
lifecycle phase and represent it is an activity across the lifecycle).
2. Addition of a new lifecycle phase of New Product Introduction (NPI) to replace the Technology
Transfer lifecycle phase to cover the initial commercialisation of the product, which is a highly
“knowledge rich” activity.
3. Introduce a new activity for Technical Product Support and Continual Improvement across the
lifecycle.
4. Introduce a vision for end-to-end (E2E) product visibility and availability, and a methodology for
transparency of product knowledge throughout the lifecycle.
Based on these enhancements, the authors propose the following Pharmaceutical Product Knowledge
Lifecycle (PPKL) Model that incorporates key knowledge generating activities and sets the stage for improved
articulation, visibility and availability of product and process knowledge.
This new model is shown in Figure 3.3.
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Pharmaceutical Product Knowledge
Lifecycle (PPKL) Model
E2E PRODUCT & PROCESS KNOWLEDGE — VISIBILITY & AVAILABILITY

PRODUCT
DEVELOPMENT

NEW PRODUCT
INTRODUCTION

R&D
to Site

R&D
to CMO

Site
to Site

COMMERCIAL
MANUFACTURING

Site
to CMO

CMO
to CMO

PRODUCT
DISCONTINUATION

CMO
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Product
Discontinuation

TECHNOLOGY & KNOWLEDGE TRANSFER ACTIVITIES
TECHNICAL PRODUCT SUPPORT & CONTINUAL IMPROVEMENT

Initial Technology
& Knowledge
Transfer

In-line Technology
& Knowledge
Transfer

© Paige Kane 2019

Figure 3.3 — Pharmaceutical Product Knowledge Lifecycle Model (PPKL) – research output Kane
2018

3.4.1

Reimagining the ICH Q10 Product Lifecycle Model - Technology Transfer

The Technology Transfer (TT) phase of the product lifecycle is of particular importance when managing
product and process knowledge. ICH Q10 emphasises that the goal of technology transfer is to:
Transfer product and process knowledge between development and manufacturing, and
within or between manufacturing sites to achieve product realisation.

According to ICH Q10 ‘This [technology transfer] knowledge forms the basis for the manufacturing process,
control strategy, process validation approach and on-going continual improvement’. With that description
in mind, the authors suggest that a more accurate description of this critical activity would actually be of
Technology and Knowledge Transfer. This is because, tacit knowledge transfer is frequently undervalued and
underestimated by the technical teams managing the technology transfer project and, in the experience of
the authors, a frequent cause of failure and of on-going process-related problems post-transfer.
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On the specific topic of Technology Transfer there are several sector guidance documents as listed below:
•

ISPE: Good Practice Guide: Technology Transfer [Third Edition] (ISPE, 2018)

•

PDA: Technical Report No. 65: Technology Transfer (PDA, 2014)

•

NIHS Japan: Guideline for Technology Transfer (NIHS, 2005)

•

WHO: WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing (World Health
Organization, 2011).

These guidance documents describe best practice and recommendations regarding technology transfer
(TT) activities. However, there is little reference to, or guidance provided relating to, the tacit knowledge
required for the success of the transfer (Lipa, Kane, Greene 2019). Although guidelines outline recommended
documents and explicit knowledge assets that should be considered in the transfer process, the tacit knowledge
about the process, which is critical and difficult to characterise and capture, receives little focus. Typically,
a small number of technical experts are sent from the sending site to the receiving site to teach, guide, and
troubleshoot for a short transitional period of time in order to share their knowledge of the product and
process, and to aid a successful transfer. Given the time and budget pressures that are often present during
this initial start-up phase for a new product introduction at the receiving site, the co-ordination of these
expert resources and the quality of the contact they have with the final commercial operations team is often
less than optimal. In many cases their time is spent assisting in the set-up of the equipment and/or process
to assist the project team to meet key project milestone, such as qualification and validation activities. Little
time is left for training and coaching the new team responsible for commercial production of the product(s)
post-handover.
The authors suggest that Technology Transfer (TT) is one particular area that could benefit from a formal set of
KM practices and tools to systematically capture the critical tacit knowledge necessary to support successful
technology transfers, with very real potential to benefit the organisation by reducing operational costs and
resources post-transfer. Work is on-going on developing these practices, and Chapter 6 of this monograph
presents some outputs of early research in this area.
Another misunderstanding that the authors have sought to address with the adaptation of the product
lifecycle model is the belief that “Technology Transfer” is a discrete phase over the life of a typical product.
In fact, throughout the life of any given product there most likely will be multiple technical transfers. Informal
benchmarking9 within the expert focus groups and KM Task Teams has observed that, for small molecule
products one could expect four or more TT events as the company continues to optimise production and
minimise costs over the product lifecycle. Indeed, technology transfers may be on-going throughout
the manufacturing phase and product discontinuation phases as products move to other nodes in the
manufacturing network, are outsourced to third party partners, or the manufacturing site is acquired by
9
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Formal benchmarking of number of Technical/Knowledge transfers in relation to capture of tacit knowledge could be an opportunity
for future research.
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a new organisation (CPhI Pharma Insights, 2016). This phenomenon is illustrated on the adapted lifecycle
model by showing multiple TT chevrons occurring throughout the product lifecycle in Figure 3.3 above.
Furthermore, technology transfer (TT) for a medicinal product typically involves multiple activities: transfer
of the active pharmaceutical ingredient (API) or drug substance (DS), transfer to the drug product (DP) or
fill/finish (FF) facility, as well as the transfer of the analytical methods to the respective testing facilities.
The last TT activity is the final transfer of all product knowledge to an archive facility when the product is
scheduled to be discontinued. This is highlighted on the PPKL Model, shown in Figure 3.3 with a final chevron,
acknowledging this transfer in the product discontinuation lifecycle phase.
The biopharmaceutical sector is not alone in addressing the challenges to transfer critical knowledge across
organisational boundaries. In 2012, APQC, at the request of 15 organisation across multiple industries,
conducted research to seek out best practices in improving the flow of knowledge during process development
(APQC, 2012a). Table 3.1 presents four high level knowledge flow best practices and associated sub-activities,
identified by this APQC research, for organisations to consider.

Table 3.1 — APQC best practices of improving the flow of knowledge during process development
(APQC, 2012a)
1. Create a strategy
for capturing
and transferring
knowledge

a) Align process development knowledge capture efforts with key
business drivers.
b) Link process development knowledge capture and transfer efforts to
existing improvement methodologies or principles.
c) Embed knowledge capture and transfer activities into the process
development stage-gate process.
d) Communicate in the language of your “customers.”

2. Develop an effective
process to capture
and transfer process
development
knowledge

a) Integrate a robust lesson learned process into process development.
b) Leverage existing groups to guide and vet knowledge.
c) Accelerate process development knowledge capture and transfer
with targeted events.
d) Distinguish among types of process development knowledge to
capture and transfer.
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Table 3.1 — APQC best practices of improving the flow of knowledge during process development
(APQC, 2012a)
3. Create organisational
support for capturing
and transferring
process development
knowledge

a) Establish explicit governance and accountability for process
development knowledge capture and transfer.
b) Capture internal customer insights by partnering with business units.
c) Create opportunities for leaders to learn from each other.
d) Adopt change management principles and engage people to foster
organisational support.
e) Use trained change agents.
f) Build and maintain a centralised, searchable repository for critical
process development knowledge.

4. Continually review
and improve the
process development
knowledge capture
and transfer process

a) Enlist and engage process development stakeholders to continuously
enhance knowledge capture and transfer efforts.
b) Use leading and lagging indicators to monitor the programme’s
impact over time.

These strategies identified by APQC could benefit the biopharmaceutical sector if used to complement the
industry-specific guidelines that address pharmaceutical products such as, control strategy, facility fit, process
qualification and analytical methods, to name but a few. The authors believe that, in particular, the concepts
identified above such as, ‘embed knowledge capture and transfer activities into the process development stagegate process’ and ‘build and maintain a centralised, searchable repository for critical process development
knowledge’, would be particularly beneficial to the success of the overall transfer process.
Returning to the APQC recommendations for improving the flow of knowledge in the Product Development
phase, and acknowledging the impact of the diversity of sites, systems and culture, the specific recommendation
of ‘Communicate in the language of your customers’, is crucial when crossing internal or external organisation
boundaries. In addition, ICH Q12 states:
‘Provisions should be made for sharing knowledge (e.g., in quality agreements and/or contracts)
that relates to product and process robustness or otherwise informs changes between the
MAH and relevant manufacturing stakeholders (research and development organisations,
manufacturers, CMOs, suppliers, etc.). ‘(International Conference on Harmonisation, 2019,
p. 31)
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However, this assumes that effective and efficient business processes for knowledge capture and curation
related to the product and process already exist at the sending site, and that the receiving site has established,
effective KM processes which stand ready to receive this knowledge as part of the transfer.
Finally, to complete this element of the lifecycle, the reimagination of the ICH Q10 product lifecycle offers an
adapted Product Knowledge Lifecycle (PPKL) Model, which replaces the phase formerly entitled Technology
Transfer with a phase entitled New Product Introduction (See Figure 3.3). This phase is intended to depict
the initial and finite activities specifically related to the first instance of commercialising of given product,
which is considered a special case of Technology Transfer. The first transition from Product Development into
Commercial Manufacturing, with the introduction of a new approved product, presents both challenges and
opportunities for an organisation, the success of which hinges on the ability of that organisation to create,
capture, communicate and curate new knowledge about that product.

3.4.2

Reimagining the ICH Q10 Product lifecycle Model –
Technical Product Support and Continual Improvement

The next element of the adapted lifecycle model the authors addressed was the introduction within the
model of an end-to-end (E2E) workstream entitled, Technical Product Support and Continual Improvement.
During the lifecycle of a product, the organisation will continue to learn and build knowledge about the
respective product. This can occur during New Product Introduction, and on-going Commercial Manufacturing,
through a variety of Technology Transfer activities. In addition to this, learnings may arise as a result of
planned and unplanned activities such as:
•

enterprise resource planning techniques established or updated to plan the shop floor workflow
necessary to execute a batch,

•

learnings from deviation resolution or product/ customer complaints,

•

additional studies for process improvement and optimisation.

The authors suggest an E2E workstream of Technical Product Support and Continual Improvement which
begins at the New Product Introduction phase when the manufacturing process is locked in order to perform
technology transfer to the initial receiving site. These support and improvement activities continue across
the product lifecycle until the product is discontinued. When, it should be noted that although the product
may no longer be manufactured, expertise and knowledge regarding the product and process may still be
needed for activities such as product complaints, and to inform next-generation product development.
If a formal process is used to capture, collate and curate the critical aspects of product and process knowledge
gained from the on-going process verification activities, such as process trending or SPC activities, CAPAs,
annual product quality reviews (APQRs) and change management oversight, the knowledge will most likely
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reside in an array of different business process systems, IT repositories and even the personal computers
belonging to subject matter experts. Further contributing to the “knowledge island” or “silos” issue raised
during the industry consultation research activities.
This Technical Product Support and Continual Improvement element of the adapted lifecycle is designed
to purposefully included to provide greater E2E knowledge transparency in order to enable enhanced E2E
knowledge flow.
Without knowledge transparency (or visibility of the knowledge assets) there can be no knowledge flow.
Without knowledge flow there can be no use of that knowledge. The consequence for the organisation of
ineffective transparency and visibility of the knowledge assets is an ineffective Pharmaceutical Quality System
(PQS). This can result in grave consequences for the patient and the business.
The acknowledgment of the rich product and knowledge generated across the product lifecycle is highlighted
in ICH Q8- Q12. However, as previously noted, the specific knowledge ‘types’ are not easy to identify in a
concise way.
A review of the literature identified two specific examples of organisations seeking to make their product
knowledge visible across the product lifecycle, not by using a complex information technology solution,
but by introducing a standard business processes that catalogues or indexes product knowledge assets as
the knowledge is created. Genentech Roche’s (Reifsynder, Waters, & Guceli, 2018) product knowledge KM
practice is outlined as the Product History File (PHF) and Pfizer (Kane & Brennan, 2014) describe a formal
business process called the Process Understanding Plan or PUP. The PUP is a business process that Kane was
involved in developing, in conjunction with other colleagues in Pfizer. One key element common to these two
business processes is the inclusion of roles and responsibilities for creation and maintenance of the product
and process knowledge assets. However, dedicated roles for E2E preservation and curation of product and
process knowledge are not be well defined across the industry, and this is significant area of opportunity for
the sector. To labor the point, when something is considered everyone’s responsibility, it is actually no one’s
responsibility. Returning to the key principle discussed in Chapter 2 of this monograph that knowledge for
the biopharmaceutical sector must be valued and managed in the same way that physical assets are managed
in the sector, development of these dedicated KM roles to enable stewardship of the knowledge assets is
crucial.
Benefits of E2E product knowledge availability and the rationale for implementing KM processes extend
beyond the articulation of KM in ICH Q10. Improvement of operational effectiveness is recorded as one of the
top drivers for implementing KM – within and outside of the biopharmaceutical sector (Knoco, 2014, 2017). It
should be noted that the business need for product and process knowledge may extend beyond the lifecycle
phase of product discontinuation, as knowledge of the product may have value beyond any regulated record
retention requirements to inform learnings of future and existing marketed products.
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A future topic of research could be the development of a practical KM practice or methodology to deliver
greater transparency of product knowledge across the product lifecycle, conceptually a Product Roadmap
that would live with the product across the lifecycle as a map of existing and necessary knowledge assets,
enabling greater transparency and therefore flow to those responsible for the product from development to
discontinuation.

3.5

The Pharmaceutical Product Knowledge Lifecycle (PPKL) Conclusions

In summary, the authors in this chapter present a novel Pharmaceutical Product Knowledge Lifecycle (PPKL)
Model as the second element of the Pharma KM Blueprint. The model is offered to encourage those responsible
for the development, manufacture and distribution of biopharmaceutical therapies to think differently about
the knowledge that is created during the lifecycle of a product. The PPKL Model proposed is an adaptation
or reimagination of the ICH Q10 Product Lifecycle published in 2008 and incorporates the following novel
features:
•

The model highlights the vision for end-to-end (E2E) product and process knowledge asset visibility,
transparency and availability in order to enable knowledge flow of critical knowledge to those that
need it throughout the product lifecycle.

•

The model includes the addition of a new lifecycle phase of New Product Introduction (NPI) to
replace the Technology Transfer lifecycle phase.

•

The model highlights that Technology Transfer is an activity that may occur multiple times across the
product lifecycle.

•

The model includes the addition of a new E2E process to capture the Technical Product Support and
Continual Improvement activities that occur across the product lifecycle.

To further develop the Pharma KM Blueprint, Chapter 4 will next introduce the House of Knowledge Excellence
(HoKE) Framework, as a strategic and a programmatic approach to managing knowledge in organisations.

A Monograph from TU Dublin Academic Press 2020
© Paige Kane and Martin Lipa

31

Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry

4.

Chapter Four
The House of Knowledge Excellence (HoKE)

This Chapter presents the third element of the Pharma KM Blueprint, namely the House of Knowledge
Excellence (HoKE) Framework.
The HoKE framework provides an opportunity to define what the authors mean by Knowledge Excellence and
how it exceeds the mere management of knowledge. “Knowledge Excellence” is not simply the application
of a series of discrete knowledge solutions, or the provision of sets of tools, but rather it is about enabling
and sustaining knowledge-focused business capabilities. The essence of the House of Knowledge Excellence
Framework offers a holistic, programmatic approach to implementing KM founded on the four pillars of
People, Process, Governance and Technology, in order to enable practical approaches to get knowledge to
flow. HoKE requires a deep understanding about “how” work gets done on a day-to-day basis and how best
to influence the behaviours of the employees or knowledge workers within the organisation. Employees must
be encouraged and enabled to think and act differently in how they seek and share knowledge.
The authors propose that the rationale for pursing capabilities in knowledge management should not be to
merely satisfy regulatory expectations, as highlighted in ICH Q10, but to deliver value to the business and
ultimately to the patient.
The genesis of the House of Knowledge Excellence (HoKE) Framework stems from the industry consultation
sessions in which biopharmaceutical sector KM practitioners highlighted the need to further define and
visualize KM Strategy and KM Program design, as well as to define practical KM approaches. As informed by
a literature review, very few biopharmaceutical organisations have implemented a programmatic approach
to knowledge management to date. Where organisations are pursuing KM, it often starts out as a discrete KM
project to address a specific knowledge gap or business driver.
The House of Knowledge Excellence (HoKE) is a practical approach that organisations may use to assist in
either the development of a KM strategy, the roll out of a holistic KM programme, or in the identification of
KM approaches that may benefit biopharmaceutical companies (Kane & Lipa, 2018). The title of the HoKE was
specifically chosen to reflect the need to move beyond the compliance expectations of managing knowledge
to realise the true business benefits of being excellent in the capture, curation and use of our knowledge.
The framework was developed by the authors and published in 2018 as a book chapter entitled The House
of Knowledge Excellence – A Framework for Success (Kane & Lipa, 2018). The HoKE framework is presented
below in Figure 4.1, however, for more detail, it is recommended that readers consult the complete chapter
in the published book.
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Figure 4.1 — House of Knowledge Excellence (HOKE) -(Kane & Lipa, 2018, p. 219)
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5.

Chapter Five
Knowledge Management
Effectiveness Evaluation (KMEE)

This chapter presents the fourth and final element of the Pharma KM Blueprint, namely the Knowledge
Management Effectiveness Evaluation (KMEE). The KMEE is an innovative diagnostic tool developed by the
authors to facilitate a structured evaluation of the effectiveness of how an organisation uses its knowledge.
The KMEE was designed to help identify actionable items that functional groups could undertake to improve
the management of their knowledge and to identify potential opportunities (i.e. gaps) for improving the
availability, access, visibility, flow and use of the knowledge assets required by the members of their group
in order to be able to conduct their day-to-day work efficiently. The development of this diagnostic tool was
inspired by analysis of data received from a KM maturity evaluation exercise executed using the APQC KM
CAT™ – KM Capability Assessment Tool within the one of the author’s organisations. Following the completion
of the APQC KM CAT™ evaluation, the author recognised that while the APQC KM Capability Assessment Tool
worked well at a business level, it did not provide enough granularity to evaluate the needs at a frontline team
or shop-floor level.
While a “one size fits all” evaluation methodology might be considered optimal in application, customising the
scoring tool has proved important to create the practical linkages between KM theory and practice. Evaluating
organisational KM maturity scored using the KM-CAT™ tool for a large organisation provides valuable business
level information, and when coupled with the KMEE tool executed at a functional group level, deep insights
into the overall effectiveness of the organization’s KM capability right down to the frontline team members
are captured. This chapter provides a real-world example of the application of the KMEE evaluation tool
within one of the author’s organisations (a large multinational biopharmaceutical company).

5.1

Evaluating Knowledge Management Maturity, Knowledge Flow,
and Improvement

Measuring KM maturity is an important element of assessing the success of any effort to improve KM practices.
Learning from a core business performance principle: ‘If you are not measuring, you’re not competing’ (Snee,
2006). This is also true when evaluating use of knowledge assets. However, measurement alone is not enough
to drive improvement. Measuring the right things is critical to the success of any organisational change effort.
It is worth reviewing an observation on KM Maturity by Kruger and Snyman.

34

A Monograph from TU Dublin Academic Press 2020
© Paige Kane and Martin Lipa

Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry

It is clear that the inability to bridge the gap between theoretical propositions and practical
usability is not only hindering knowledge management practitioners from successfully
assessing the level of knowledge management maturity reached within organisations but,
more importantly, is making managers lose faith in knowledge management as a strategic
enabler. (Kruger & Snyman, 2007)

The authors have direct experience of using the APQC KM CAT™ – KM Capability Assessment Tool in multiple
instances within two large biopharmaceutical companies and one biotechnology industry collaboration
group. It was found that in practice, the KM CAT™ tool was informative to assess KM Program and high-level
organisational maturity. A key benefit of using the KM CAT™ is the ability to benchmark the maturity value for
a given organisation against the extensive APQC data set (both sector centric indices and industry agnostic
indices). However, when executed at the divisional level, the KM CAT™ proved difficult to translate the findings
from the maturity assessment into specific actions for individual teams. A helpful analogy to consider is how
a global stock market index can be used to describe the overall performance of a sector but provides little
insight into the performance of individual businesses included in the index average. This reflection, and the
need to close the ‘knowing – doing gap’, lead the authors back to the Kruger and Snyman observation above.
Diving deeper into the maturity assessment, the challenge with the KM CAT™ was multifaceted. Evaluation of
the feedback from participants revealed the following:
1. The structure and taxonomy used within the KM-CAT™ question-set required deep experience
with the tool to “translate” the questions for participants. Participants were unfamiliar with much
of the KM specific terminology, for example when questioned about access to a Expertise Locator
KM Tool (a searchable tool to help them find an expert in a subject area within their organization)
participants were not aware that a staff contact database system available on their internal company
intranet was in fact an Expertise Locator tool.
2. Participants felt many of the standard benchmarking questions were not relevant to them as
individuals or to their teams (e.g. details related to overall budget for KM, leadership sponsorship
for KM etc.), and therefore could not answer those questions with confidence.
3. Participants felt that many capabilities which they actually demonstrated were not recognised or
reported through the KM-CAT™ tool due to the scoring methodology i.e., groups felt they were
acknowledged for progress or unless all the capabilities within a given maturity level were met.
4. Benchmarking results were not presented at a level that the individual teams felt they could
meaningfully action.
5. KM Advocates10 within some teams were frustrated that the level of assessment didn’t clearly
identify practical examples of how individual groups could improve (as related to item 4 above).
6. The full assessment took multiple hours to complete: it was too time-consuming with limited
“relevance” in the view of participants at lower level teams.
10

KM Advocates were employees within a functional team passionate about KM approaches who helped their team avail of enterprise
KM tools and approaches.

A Monograph from TU Dublin Academic Press 2020
© Paige Kane and Martin Lipa

35

Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry
Upon consideration of the feedback, the authors considered one simple solution would be to take the KMCAT™ deeper in to the organisation, however they did not believe the sentiments presented around relevance,
terminology, and reporting detail would be addressed by the KM-CAT™ alone. Based directly on this feedback,
they sought to develop a KM maturity evaluation tool that was:
•

Relevant to smaller teams/ functional groups, focusing on items within their control

•

Could be used as a baseline to further measure specific team capability

•

Was capable of articulating gaps within the teams

•

Included a scoring template that could recognise the achievement of individual capabilities

•

Included a scoring template that enabled prioritising and closing identified gaps

•

Could be administered by a local KM advocate, and did not require an SME from the KM Program
Team to “translate”.

Before discussing the details of the resulting KMEE Diagnostic tool developed by the authors, it is first useful
to understand the key features and scoring mechanisms embedded within the APQC KM-CAT™ tool.

5.2

APQC’s Knowledge Management Capability Assessment Tool™ (KM-CAT™)

According to APQC the APQC’s Knowledge Management Capability Assessment Tool™ (KM-CAT™) helps
an organisation assess its capabilities and maturity in knowledge management (KM) and to focus its KM
investments to produce the highest return on value. This assessment maps the current ‘as-is’ state of KM and
the knowledge flow processes within an organisation in order to:
•

Measure the current maturity of the enablers and infrastructures employed,

•

Evaluate the current status of knowledge flow processes and supporting approaches,

•

Set an objective for the improvement of business processes through the flow of knowledge,

•

Guide the evolution of organisational change, and

•

Compare or benchmark with similar efforts of other internal units or external organizations.

The KM-CAT™ is divided into four major sections with subcategories as shown in Table 5.1 below.
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Table 5.1 — APQC KM-CAT™ - Four major sections with subcategories

Strategy

People

Process

Content and Information Technology

•

Objectives

•

Business case

•

Budgets

•

Resources

•

Governance structure and roles

•

Change management

•

Communication

•

Knowledge flow process

•

KM approaches

•

Measurement

•

Content management

•

IT processes and tools

Within each section, capabilities are described ranging in maturity levels 1-5. APQC describes the levels of
Maturity (APQC, 2010) as:
•

Level 1 — an organisation is aware that it has a problem retaining and sharing knowledge.

•

Level 2 — initial knowledge approaches are in place. The focus is on helping localised knowledge
flow and adding value.

•

Level 3 — the knowledge flow processes are standardised, and the focus is on meeting business
requirements, achieving results, and developing a supporting infrastructure.

•

Level 4 — the KM efforts align with the organisation’s business objectives and the focus is on
leveraging core knowledge assets across the enterprise.

•

Level 5 — KM practices are embedded in key business processes and the focus is on the competency
of the business.

Scoring of the KM-CAT™ requires that all capabilities within that level must be demonstrated in order to
achieve a score in the level (e.g. level 1, 2, 3 etc.). In addition, all capabilities associated with any given level
below the current maturity level must also be demonstrated within the organisation in order to be considered
to have achieved that level. To further explain the scoring, an excerpt of the KM-CAT™ KM Approaches & Tools
section is shown in Table 5.2 below:
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Table 5.2 — Example of APQC KM-CAT™ data collection sheet for a given capability
LEVEL

ACHIEVED
Y/N

CAPABILITY
Standard methods are used to capture and retain valuable knowledge.
The organization uses replicable knowledge flow processes and KM approaches.
Enablers and infrastructure support knowledge flow process.

3

KM methods and tools are available to knowledge workers on demand.
KM maturity and capabilities are assessed.
A KM "resource center" is established, including KM reading materials, case studies,
and presentations.
Some KM approaches to support knowledge flow (e.g., communities of practice,
knowledge capture, lessons learned, and expertise location) are implemented in parts
of the organization.

2

Knowledge maps for each initial KM focus area identify content and knowledge needs/
gaps.
Core business processes that require enhanced knowledge flow are identified.

1

Story-telling and one-to-one exchanges are the primary approaches used for knowledge
transfer.

For example, three capabilities are required to be in place in order to meet the criteria for Level 2 for this KM
Capability assessment. All three capabilities within Level 2 must be met, in addition to the single capability
required at Level 1. If the Level 1 capability is not demonstrated, even if all Level 2 capabilities were achieved,
the organisation would not score KM maturity at Level 2.
The authors recognise that, while there are many positives with the KM-CAT™, the scoring methodology and
process is particularly challenging when trying to evaluate and engage functional teams. While the overall
rationale for scoring11 is sound, the results as presented by the APQC methodology, are not particularly
insightful at the function level. Table 5.3 describes challenges and potential solutions the authors considered
when designing an updated tool.

11

38

Scoring methodology is similar to that of Malcolm Baldrich Quality Award, in which APQC was also involved in the development
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Table 5.3 — Opportunities for KM-CAT™ Tool

5.3

KM-CAT™ Challenge

Potential Solution

Administration of KM-CAT™ questions
required deep experience with the tool
to “translate” for participants

Develop a set of customized questions
maintaining intent of the KM-CAT™ to retain the
ability to benchmark with APQC

Questions around strategy and
resources and were not relevant to most
participants

Identify questions relevant to individual teams
working in the business (not the KM Team)

All capability in a level must be met to
get credit for them

Devise a methodology score progress within a
maturity level to credit each capability met

Scope of KM-CAT™ was too high level to
enable local teams to understand where
they fit

Design the tool that it is relevant for individual
teams yet still maintains integrity, to enable
rolled up to the KM-CAT™

Assessment too long

Identify relevant/applicable capabilities for
functional teams (items within their control) in
order to simplify

Need for a supplemental tool for localised functional KM Assessments

While acknowledging that the KM-CAT™ is suitable for measuring overall organisation and KM programme
maturity /capability, the authors endeavored to create a focused capability diagnostic tool aimed at smaller
groups/teams such that it:
1) Is customised to reflect specific KM tools and processes within the organisation – drives engagement
at the individual or team level, and not at the KM Programme level. In addition, the customisation
aids in developing specific action plans.
2) Is scored to clearly acknowledge all capabilities met within levels, with “credit given” even if not
all capabilities within a given level have been achieved. Participant feedback found this very
frustrating.
3) Provides visual results of specific scoring to enable future progress tracking.
4) Provides a mechanism to prioritise gaps identified.
5) Provides templates for reporting and action planning. i.e. Pre-populated templates with specific
recommendations, outlining the benefit to the organisation for closing the gap.
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5.4

Development of the Knowledge Management Effectiveness Evaluation
(KMEE) Tool:

The development of the KMEE tool included the following steps.
1) Each capability within the APQC KM-CAT™ tool was first reviewed for relevance for each individual
group – e.g. a smaller part of the organisation whose primary responsibly was supporting product
realisation and continual improvement, and did not have a responsibility for developing the overall
Divisional KM programme.
2) Capabilities deemed relevant from the APQC KM-CAT™ tool were then supplemented with specific
organisational “translations” of the capability to clarify the requirements and relevance.
3) Capabilities were organised via the sections and sub-sections of the original APQC KM-CAT™ tool,
and each of the criteria for the maturity level were also included.
Note, the version of the APQC KM-CAT™ tool that was leveraged for further development contained 4 Sections
and 12 sub-sections and 151 individual capabilities.
After review and evaluation of the full APQC KM-CAT™ assessment tool, the authors determined that 28
individual capabilities arranged into 3 sub-categories/focus areas would be most suited to individual groups
within the biopharmaceutical organisation seeking to improve its KM maturity and knowledge flow.
These are shown in Table 5.4 below:

Table 5.4 — APQC KM CAT™ areas to be used in the KMEE
Capabilities
Identified

Sections

Subcategories

Process

PR1) Knowledge flow process
(PR2) KM approaches
(PR3) Measurement

12

People

(PP3) Change management
(PP4) Communication

11

Content and Information
Technology

(IT1) Content management/
Information Technology processes
and tools

5

Each of these sections have sub-categories which have been labeled as in the APQC Tool (PP3, PP4, PR1, PR2,
PR3, IT1). Note, that in the full APQC assessment there are additional sub-categories not represented in
the KMEE. Within each of the KMEE levels of maturity (levels 1-5) the number of associated capabilities are
identified, are shown in Table 5.5:
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Table 5.5 — Capability description within maturity levels depicted
Level

Description of Maturity Level

Number of Capabilities

1

Initiate

4

2

Develop

7

3

Standardise

9

4

Optimise

5

5

Innovate

3

The modified KMEE evaluation tool is now shown in the next three tables. Table 5.6 related to Content and
IT capabilities, Table 5.7 evaluates People capabilities, Table 5.8 evaluates Process and Knowledge Flow
capabilities.
Table 5.6 — KMEE Content and Information Technology (IT)
Category

APQC Capability
Description

KMEE Function Specific
Description of Capability

1

Content and IT
(IT1) Content
Management
Processes

General document
management processes are
in place.

General document management processes are
in place. What are they?

1

Content and IT
(IT1) Content
Management
Processes

Existing information
technologies (IT) and tools
are leveraged and used
where possible.

Existing KM information technologies (IT) and
tools are leveraged and used where possible
(i.e. expertise locator, XX discussion boards,
XXX product knowledge system XXX, Enterprise
Search)

2

Content and IT
(IT1) Content
Management
Processes

Content is identified and
organised at business unit or
domain.

Knowledge/Content is identified and organized
at a group level or workflow level (may be
sporadic)- list the methodology

3

Content and IT
(IT1) Content
Management
Processes

Standardized taxonomies for
classifying core knowledge
assets exist.

Your group uses a standard naming convention
for storing content - what is the methodology?

Content management
workflows are standardized.

Content management workflows are
standardized. All colleagues know where to store
their content on shared spaces with supporting
document management practices - list the
practices

Level

3

Content and IT
(IT1) Content
Management
Processes
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Table 5.7 — KMEE People Capabilities
Level

42

KMEE Function Specific
Description of Capability

Category

APQC Capability Description

1

People:
(PP3) Change
Management

Current state assessment of
successes and problems in
knowledge sharing include
the identification of potential
barriers and competing issues
impacting knowledge flow
required for business results.

Have you done an assessment to gauge KM
issues in your group/site? If so, do you know
the issues and barriers?

2

People:
(PP3) Change
Management

Education and training plans
are in place to support initial
KM projects.

All colleagues in your group have been trained
on the core KM approaches for all GTO - i.e.
expertise locator, XX discussion boards,
Enterprise Search, Lessons learned portal,
enterprise search. And if part of colleague’s
roles- the product knowledge system XXX,
Technology Transfer system (if relevant).

3

People:
(PP3) Change
Management

Barriers to sharing and using
knowledge are identified and
addressed.

Your group has identified barriers to sharing
and using knowledge and have addressed them
(with help from the KM team if needed) - list
the barriers and solutions

3

People:
(PP3) Change
Management

Accountability is expanded for
knowledge flow processes and
approaches.

Groups outside of the official KM group are
working to ensure that knowledge flows
across the site/business (e.g. collaborative
development process XXX, etc.) - list how your
team is leveraging

3

People:
(PP3) Change
Management

KM advocates are in place
across the enterprise.

Colleagues who are responsible for advocating
for KM projects / approaches are in place in
your organization (site for sites and center
groups for center)

4

People:
(PP3) Change
Management

Formal recognition is given for
KM efforts, success, and lessons
learned.

Formal recognition is given for KM efforts,
success, and lessons learned within your group
and across other groups -give examples

4

People:
(PP3) Change
Management

KM training is provided to new
hires to help make KM a part of
the culture.

Overview of the division/group specific KM
approaches are provided to new hires or
colleagues that have joined the organisation
from another part of the business

4

People:
(PP3) Change
Management

KM advocates have
accountability for KM results.

Colleagues responsible for advocating for KM
projects / approaches (site for sites and center
groups for center) have accountability/ success
for group KM approaches in their performance
objectives
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Table 5.7 — KMEE People Capabilities
Level

KMEE Function Specific
Description of Capability

Category

APQC Capability Description

5

People:
(PP3) Change
Management

KM is aligned with talent
management and leadership
development.

Talent management processes leverage KM
approaches/ processes (e.g. current online
profiles, expertise locator) to ensure that talent
& experience is visible to all colleagues- also
leaders leverage the expertise locator/profiles
to ID potential diverse candidates for new
development opportunities/ roles

2

People: (PP4)
Communication

KM advocates discuss the
value of KM to the business
with senior leaders and key
stakeholders.

KM advocates (site or programme colleagues)
have been identified for your group and engage
with leaders and managers to discuss the KM
approaches/ projects and value to the group

3

People: (PP4)
Communication

Success stories from initial
KM projects are broadly
communicated.

Has your site or group communicated any
success stories levering KM, if so what or what
are the opportunities?
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Table 5.8 — KMEE Process and Knowledge Flow Processes
Level

44

KMEE Function Specific
Description of Capability

Category

APQC Capability Description

2

Process: (PR1)
Knowledge
Flow Process

Stabilized knowledge flow
processes are embedded in KM
approaches e.g., Communities
of Practice, Lessons Learned,
After Action Review, etc.

List the processes that enable knowledge to flow
across groups, projects, etc. Examples could be
Lessons Learned, CoPs, discussion boards

3

Process: (PR1)
Knowledge
Flow Process

Standardised knowledge flow
processes are used across
multiple instances or situations.

What are the standardised processes to enable
the flow of knowledge across multiple groups in
the organisation

4

Process: (PR1)
Knowledge
Flow Process

Knowledge flow processes are
embedded in core business
processes and domains.

Your group us leveraging KM concepts of
knowledge flow and capture into the design of
"systems", business processes (e.g. collaborative
development process XXX, Investigations using
KM techniques. Etc.)

2

Process:
(PR2) KM
Approaches

Knowledge maps for each initial
KM focus areas identify content
and knowledge needs/gaps.

Your group has participated in a Knowledge
mapping exercise and gaps have been identified.
List the date of the exercise

2

Process:
(PR2) KM
Approaches

Core business processes that
require enhanced knowledge
flow identified.

Your group understand what core business
processes would benefit from applying the "KM"
lens to help with knowledge flow- list them

3

Process:
(PR2) KM
Approaches

Standard methods are used
to capture and retain valuable
individual knowledge

We have methodologies (plural) for capturing
the knowledge of individuals.

3

Process:
(PR2) KM
Approaches

KM maturity and capabilities
are assessed.

KM maturity and capabilities are assessed using
the Knowledge management Effectiveness
Evaluation (KMEE) Tool – list date

4

Process:
(PR2) KM
Approaches

KM competency maps exist for
individual roles and/or jobs.

Individual roles / jobs within the group clearly
state what knowledge is needed and generated
in the specific role

5

Process:
(PR2) KM
Approaches

KM approaches, methodologies
and tools are integrated
with process improvement,
organizational development,
and learning approaches.

List the KM approaches, methodologies and
tools you use that are integrated with process
improvement, organisational development, and
learning approaches e.g. when we do an OpEx
project, innovation project, troubleshooting,
etc., are we also using the KM tools/processes?

5

Process:
(PR2) KM
Approaches

KM becomes a "core
competency" of the
organisation.

What is the evidence that KM is a "core
competency" and competitive advantage of your
group

1

Process: (PR3)
Measurement

An assessment of critical
knowledge in current business
processes / domains is
conducted.

Has your group participated in a Knowledge
Mapping exercise? If so, have you implemented
the remediation plan?

2

Process: (PR3)
Measurement

Local KM activity measures are
in place and used.

KM Advocate or group leader measuring/
monitoring the use of KM activity within the
group e.g. the participation in discussion boards
‘X’, the updating of online profiles, etc. - list the
examples
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5.4.1

Scoring Methodology:

To evaluate the modified KMEE tool, a series of focus groups were performed to assess if each capability
criteria (using the customised questions) were met. A scoring mechanism was designed to reflect capability
attainment, which was visually represented in a heat map. Examples of focus groups heat maps are presented
for a team with low KM maturity versus a team demonstrating higher KM maturity in Tables 5.9 and 5.10
respectively below:
Table 5.9 — Focus group demonstrating low KM Capability:
Green cells indicate achieved, Grey indicate N/A
PP3 Change
Management

PP4
Communication

PR1 Knowledge
Flow

PR2 KM
Approaches

PR3
Measurement

IT1 Management
Processes

L1

L2

L2

L2

L1

L1

L2

L3

L3

L2

L2

L1

L4

L3

L2

L3

L3

L3

L3

L4

L3

L4

L5

L4

L5

L3

L4
L5

In contrast, results from the second focus group that demonstrated a more mature KM capability is shown
below:
Table 5.10 — Focus group demonstrating higher KM Capability:
Green cells indicate achieved, Grey indicate N/A
PP3 Change
Management

PP4
Communication

PR1 Knowledge
Flow

PR2 KM
Approaches

PR3
Measurement

IT1 Management
Processes

L1

L2

L2

L2

L1

L1

L2

L3

L3

L2

L2

L1

L4

L3

L2

L3

L3

L3

L3

L4

L3

L4

L5

L4

L5

L3

L4
L5
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Reviewing the contrasting results of the two example teams, who all belong to the same organisation, one can
recognise the level of detail reported is invaluable for each team to understand their specific KM capabilities,
and learn which approaches can be used to improve the KM capabilities and knowledge flow within their
team, helping them to work more effectively and purposefully in the future.
In this example, a business decision by the leadership of the case-study organization, all teams aim to reach a
Level 3 in maturity as the initial maturity performance improvement target. As such, a report was developed
to show the gaps (if any) to reach capability of both the internal goal of Level 3 maturity, as well as what would
be required to strive towards a Level 5 maturity, the highest level of maturity on the model. Figure 5.1 is an
example of how these results were visualised for leadership to aid their comprehension and ownership of the
organisational changes required.
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Figure 5.1 — Blue indicates the number of capabilities required to fill the gap to achieve level 3
maturity, Green is the gap of capabilities to reach level 5 maturity.
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5.4.2

KMEE Reporting and KM Plan – A Roadmap to KM Capability Improvement

To assist each functional area, a KM plan template was developed to suggest opportunities and methodologies
to close the gaps, as well as to articulate business benefits to build KM capability. The full report provided to
each team was presented and included the following:
•

The rationale for the KM Maturity Assessment

•

The date of focus group/assessment

•

Focus group participants and facilitators

•

What was working well

•

Discussion Insights

•

For each Category (People, Process, Content & IT) the following were provided

•

»

A listing of gaps noted to level 3 (L3)12

»

Recommendation for closing the gap

Prioritisation map that was developed based on the perceived ease to implement the gap closure
and the value of closing the gap.

Each team was also provided their detailed KMEE evaluation spreadsheet with assessment notes and scoring
so that individual groups could manage their implementation plan and track progress.
The full case study described in the previous sections is published as a component of Kane’s PhD thesis and
can be found in the TU Dublin Arrow site https://arrow.dit.ie/sciendoc/210/ .

5.5

Conclusion

The KMEE tool was developed to provide a practical link between the KM theoretical proposition and the
practical business application that Kruger and Snyman indicated is so critical for the success of KM programs.
This KMEE tool, with the help of a KM practitioner, translates KM terminology into local business nomenclature,
thus enabling meaningful engagement with knowledge workers and ensuring an efficient and effective
evaluation of the knowledge flow process within organisations, right down to front line team member level.
It could be argued that the model is very closely linked to the APQC KM-CAT™, that was by design. However,
feedback from the management teams involved in the case study pilots indicated a strong preference to
maintain a link back to a “proven” benchmarking tool, hence building a positive case for the strong linkage to
the APQC Maturity tool. In addition, the action plans arising from the completion of the KMEE tool provided
teams with recommendations that were in the direct control of the team to enable them to improve the
management and sharing of their knowledge.
12

As the business focus was to have all groups achieve a level 3 (L3) capability, focus was on closing the gaps for L3 for the fiscal year
of the study.
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6.

Chapter Six
Evolving Research: Presentation of a
Framework to Enhance Knowledge Transfer

This chapter concludes the monograph by presenting early stage research into effective Knowledge
Management during Technology Transfer in the format of a Knowledge Transfer Enhancement Framework
(KTE Framework).
The KTE Framework evolved over a series of brainstorming meetings and workshops, based on the experience
of the authors (including experience with KM best practices across industries), and by applying a well-known
Lean Six Sigma improvement methodology of Plan, Do, Check, Act (or PDCA). The KTE Framework (Figure 6.1)
is divided into four stages, namely:
•
•
•
•

Stage 1:
Stage 2:
Stage 3:
Stage 4:

KT Readiness Planning
KT Execution
KT Effectiveness Assessment
KT Action Plan.

The KTE Framework is depicted in Figure 6.1.

Figure 6.1 — The KTE Framework (original contribution Lipa 2020)
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Further detail on the purpose and intended outcome of each of the four stages is presented in Figure 6.2.

Figure 6.2 — Expanded KTE view of purpose and intended outcome of each of the
four stages (original contribution Lipa 2020)

Work is on-going and it is anticipated that the development of this framework and an associated toolkit to
enhance knowledge transfer will be published in the near future.
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